Emerging infectious diseases research prevail i, III, v and prevac mali
Active Awarded Last action
- Contract number
- 75N91022F00018
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,008,921
Award facts
- Contract value 100% obligated
- $4,008,921.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | -$1,145,038 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $5,153,959 |
About this award
This federal contract award, valued at $4,008,921.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports the Emerging Infectious Diseases Research PREVAIL I, III, V, and PREVAC Mali programs, which focus on research related to infectious diseases. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type and has an ultimate completion date of September 15, 2027. The contract does not have a set-aside designation. Leidos Biomedical Research Inc. has subcontracted a portion of the work to Mitchell Group, Inc., a minority-owned, veteran-owned small business, to provide operational support, management consulting, and program evaluation services for the clinical research activities.
Quick answers
Who was awarded contract 75N91022F00018?
75N91022F00018 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 16, 2022.
How much is contract 75N91022F00018 worth?
The government has obligated $4,008,921 on 75N91022F00018.
Which agency awarded contract 75N91022F00018?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00018, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00018 an order under another contract?
Yes. 75N91022F00018 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00018 competed?
The extent of competition for 75N91022F00018 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award